HN0090

HN0090 is a preclinical-stage small molecule drug candidate being developed by Huinuo Biopharmaceutical Technology (also known as Phaenothera) for the treatment of drug-resistant bacterial infections. The program is currently in the IND-enabling phase, targeting unmet medical needs in the field of antimicrobial resistance. While the specific biological target and mechanism of action have not been publicly disclosed, HN0090 is part of a specialized portfolio of anti-infective agents designed to combat multi-drug resistant pathogens. Huinuo Biopharmaceutical is a China-based biotechnology company focused on the discovery and development of innovative therapies for infectious diseases.